|
1
|
Felson DT: Developments in the clinical
understanding of osteoarthritis. Arthritis Res Ther. 11:2032009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Felson DT and Neogi T: Osteoarthritis: is
it a disease of cartilage or of bone? Arthritis Rheum. 50:341–344.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song L, Liu M, Ono N, Bringhurst FR,
Kronenberg HM and Guo J: Loss of wnt/β-catenin signaling causes
cell fate shift of preosteoblasts from osteoblasts to adipocytes. J
Bone Miner Res. 27:2344–2358. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen B, Li XD, Liu DX, Wang H, Xie P, Liu
ZY, Hou GQ, Chang B and Du SX: Canonical Wnt signaling is required
for Panax notoginseng saponin-mediated attenuation of the RANKL/OPG
ratio in bone marrow stromal cells during osteogenic
differentiation. Phytomedicine. 19:1029–1034. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spencer GJ, Utting JC, Etheridge SL,
Arnett TR and Genever PG: Wnt signalling in osteoblasts regulates
expression of the receptor activator of NFkappaB ligand and
inhibits osteoclastogenesis in vitro. J Cell Sci. 119:1283–1296.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moester MJ, Papapoulos SE, Löwik CW and
van Bezooijen RL: Sclerostin: current knowledge and future
perspectives. Calcif Tissue Int. 87:99–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Bezooijen RL, Roelen BA, Visser A, van
der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE,
ten Dijke P and Löwik CW: Sclerostin is an osteocyte-expressed
negative regulator of bone formation, but not a classical BMP
antagonist. J Exp Med. 199:805–814. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Poole KE, van Bezooijen RL, Loveridge N,
Hamersma H, Papapoulos SE, Löwik CW and Reeve J: Sclerostin is a
delayed secreted product of osteocytes that inhibits bone
formation. FASEB J. 19:1842–1844. 2005.PubMed/NCBI
|
|
9
|
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang
J, Harris SE and Wu D: Sclerostin binds to LRP5/6 and antagonizes
canonical Wnt signaling. J Biol Chem. 280:19883–19887. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Semënov M, Tamai K and He X: SOST is a
ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem.
280:26770–26775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Altman RD: Criteria for classification of
clinical osteoarthritis. J Rheumatol Suppl. 27:10–12.
1991.PubMed/NCBI
|
|
12
|
Zhang W, Moskowitz RW, Nuki G, Abramson S,
Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty
M, et al: OARSI recommendations for the management of hip and knee
osteoarthritis, Part II: OARSI evidence-based, expert consensus
guidelines. Osteoarthritis Cartilage. 16:137–162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bobinac D, Spanjol J, Zoricic S and Maric
I: Changes in articular cartilage and subchondral bone
histomorphometry in osteoarthritic knee joints in humans. Bone.
32:284–290. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burr DB: Anatomy and physiology of the
mineralized tissues: role in the pathogenesis of osteoarthro sis.
Osteoarthritis Cartilage. 12(Suppl A): S20–30. 2004. View Article : Google Scholar
|
|
15
|
Prasadam I, van Gennip S, Friis T, Shi W,
Crawford R and Xiao Y: ERK-1/2 and p38 in the regulation of
hypertrophic changes of normal articular cartilage chondrocytes
induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum.
62:1349–1360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanchez C, Deberg MA, Piccardi N, Msika P,
Reginster JY and Henrotin YE: Osteoblasts from the sclerotic
subchondral bone downregulate aggrecan but upregulate
metalloproteinases expression by chondrocytes. This effect is
mimicked by interleukin-6, -1beta and oncostatin M pre-treated
non-sclerotic osteoblasts. Osteoarthritis Cartilage. 13:979–987.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karsdal MA, Leeming DJ, Dam EB, Henriksen
K, Alexandersen P, Pastoureau P, Altman RD and Christiansen C:
Should subchondral bone turnover be targeted when treating
osteoarthritis? Osteoarthritis Cartilage. 16:638–646. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trouvin AP and Goëb V: Receptor activator
of nuclear factor-κB ligand and osteoprotegerin: maintaining the
balance to prevent bone loss. Clin Interv Aging. 5:345–354.
2010.
|
|
19
|
Bodine PV: Wnt signaling control of bone
cell apoptosis. Cell Res. 18:248–253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma B, Zhong L, van Blitterswijk CA, Post
JN and Karperien M: T cell factor 4 is a pro-catabolic and
apoptotic factor in human articular chondrocytes by potentiating
nuclear factor κB signaling. J Biol Chem. 288:17552–17558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Winkler DG, Sutherland MK, Geoghegan JC,
Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR,
Staehling-Hampton K, et al: Osteocyte control of bone formation via
sclerostin, a novel BMP antagonist. EMBO J. 22:6267–6276. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Bezooijen RL, Bronckers AL, Gortzak
RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ,
Van Hul W, Hamersma H, Dikkers FG, et al: Sclerostin in mineralized
matrices and van Buchem disease. J Dent Res. 88:569–574. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krause C, Korchynskyi O, de Rooij K,
Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides
AN, Mueller TD, Löwik CW and ten Dijke P: Distinct modes of
inhibition by sclerostin on bone morphogenetic protein and Wnt
signaling pathways. J Biol Chem. 285:41614–41626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robling AG, Niziolek PJ, Baldridge LA,
Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido
TM, Harris SE, et al: Mechanical stimulation of bone in vivo
reduces osteocyte expression of Sost/sclerostin. J Biol Chem.
283:5866–5875. 2008. View Article : Google Scholar
|
|
25
|
Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang
J, Li Y, Feng G, Gao X and He L: Sclerostin mediates bone response
to mechanical unloading through antagonizing Wnt/beta-catenin
signaling. J Bone Miner Res. 24:1651–1661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bonewald LF and Johnson ML: Osteocytes,
mechanosensing and Wnt signaling. Bone. 42:606–615. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burr DB: The importance of subchondral
bone in the progression of osteoarthritis. J Rheumatol Suppl.
70:77–80. 2004.PubMed/NCBI
|
|
28
|
Goldring MB and Goldring SR: Articular
cartilage and subchondral bone in the pathogenesis of
osteoarthritis. Ann N Y Acad Sci. 1192:230–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Madry H, van Dijk CN and Mueller-Gerbl M:
The basic science of the subchondral bone. Knee Surg Sports
Traumatol Arthrosc. 18:419–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Funck-Brentano T, Bouaziz W, Marty C,
Geoffroy V, Hay E and Cohen-Solal M: Dkk-1-mediated inhibition of
Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis
Rheumatol. 66:3028–3039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ominsky M, Warmington K, Asuncion F, Tan
H, Grisanti M, Geng Z, Stephens T, Henry A, Lawson A, Lightwood D,
et al: Sclerostin monoclonal antibody treatment increases bone
strength in aged osteopenic ovariectomized rats. J Bone Miner Res.
21(Suppl 1): S442006.
|
